PAI
IOVA icon

Palo Alto Investors’s Iovance Biotherapeutics IOVA Stock Holding History

Palo Alto Investors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.3M Sell
6,349,563
-767,113
-11% -$2.45M 3.41% 11
2025
Q4 		$19.4M Sell
7,116,676
-501,456
-7% -$1.16M 2.7% 11
2025
Q3 		$16.5M Buy
7,618,132
+4,188,803
+122% +$9.89M 3.06% 9
2025
Q2 		$5.9M Buy
3,429,329
+218,015
+7% +$542K 1.26% 19
2025
Q1 		$10.7M Buy
3,211,314
+169,629
+6% +$875K 2.04% 14
2024
Q4 		$22.5M Hold
3,041,685
– – 3.49% 11
2024
Q3 		$28.6M Buy
3,041,685
+925,282
+44% +$8.77M 3.71% 10
2024
Q2 		$17M Buy
2,116,403
+3,592
+0.2% +$38.5K 1.97% 12
2024
Q1 		$31.3M Buy
2,112,811
+6,019
+0.3% +$70.1K 3.53% 9
2023
Q4 		$17.1M Buy
+2,106,792
New +$11M 1.54% 14

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Palo Alto Investors's IOVA Position: Q1 2026 in Review

Palo Alto Investors reduced its Iovance Biotherapeutics (IOVA) stake by 11% in Q1 2026, selling an estimated $2.45M and leaving 6,349,563 shares worth $22.3M. The position accounts for 3.41% of the portfolio, ranked #11.

Palo Alto Investors first reported a position in IOVA in Q4 2023 and has held it in 10 quarters since. The position peaked at $31.3M in Q1 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Palo Alto Investors held 6,349,563 shares of Iovance Biotherapeutics worth $22.3M as of Q1 2026.
  • Palo Alto Investors sold 767,113 Iovance Biotherapeutics shares in Q1 2026, an estimated $2.45M.
  • Iovance Biotherapeutics made up 3.41% of Palo Alto Investors's portfolio in Q1 2026, its #11 holding.
  • Palo Alto Investors first reported a position in Iovance Biotherapeutics in Q4 2023 and has held it in 10 quarters since.
  • Palo Alto Investors's Iovance Biotherapeutics position peaked at $31.3M in Q1 2024.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Palo Alto Investors's 13F filing for Q1 2026, filed 15 May 2026.